C3 Granulopathy during pregnancy tied to higher preeclampsia and premature births: Study
A new study published in the journal of BMC Nephrology showed that C3 Granulopathy + pregnancy is linked to a higher risk of preeclampsia and premature birth compared to healthy pregnancies, though it does not increase the risk of spontaneous miscarriage. Additionally, a mild but significant decline in renal function (as indicated by creatinine and eGFR levels) is observed. These findings highlight the importance of multidisciplinary care for pregnant patients with C3G due to the elevated risks of adverse renal and obstetric outcomes.
The ultra-rare glomerular illness known as C3 Glomerulopathy (C3G) is caused by deregulation of the alternative complement system. Within ten years of diagnosis, between 30 and 50 percent of adult patients develop end-stage kidney disease (ESKD). The results for women who become pregnant while suffering from C3 Glomerulopathy (C3G) are little understood. The ultra-rare nature of C3G and the relatively recent realization that the illness encompasses much more than dense deposit disease (DDD) or membranoproliferative glomerulonephritis type II (MPGN II) are reflected in this knowledge gap.
The objectives of this study were to objectively describe the pregnancy outcomes for patients with C3G, identify potential risk factors or conditions that could lead to adverse events for the mother or the unborn child during and after pregnancy, and generate data that nephrologists could use to advise patients and their families about pregnancy in the context of C3G, better educating them about the risks involved.
Female participants with at least one pregnancy and adequate renal/obstetric data were included in the University of Iowa's C3G Natural History This study provided they satisfied consensus biopsy criteria. Clinical history, renal function tests, and complement testing were among the evaluated data in order to determine the inherited and/or acquired causes of complement dysregulation. The results and changes in clinical biomarkers before and after pregnancy were compared using the appropriate t-tests or z-tests. Risk for preeclampsia, early delivery, and progression to ESKD were estimated using nonlinear regression and relative risk.
There were 37 pregnancies and 27 births among moms whose C3G manifested either before or during pregnancy (C3G + P). When compared to healthy pregnancies and pregnancies of mothers with other glomerular disorders, 12 births (44%) were preterm, and 16 (59%) were linked to antepartum preeclampsia, an increased risk.
Preexisting hypertension, a known cause of complement dysregulation, and an eGFR of less than 60 ml/min/1.73 m2 before pregnancy were risk factors for problems. Additionally, these risk variables predict the development of ESKD within 5 (5/32, 16%) and 10 (6/32, 19%) years after pregnancy.
Mothers who had ESKD within five to ten years of becoming pregnant had considerably lower individual pre- and post-pregnancy eGFRs. Overall, C3G + P was linked to a slight but substantial decline in renal function, as evaluated by creatinine and eGFR. The increased risk of severe renal and obstetric outcomes highlights the importance of multidisciplinary treatment for pregnant individuals with C3G.
Source:
Fergus, L. O., Waldmann, M., Hall, M. D., Vining, L., Hall, J., Liu, T., Zhang, Y., Walker, P. J., Smith, R. J. H., & Nester, C. M. (2025). Pregnancy outcomes in C3 glomerulopathy: a retrospective review. BMC Nephrology, 26(1), 238. https://doi.org/10.1186/s12882-025-04118-y
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.